medicines


US pressures Australia for stronger TPP biologics monopolies
According to the Bloomberg, Senator Hatch said “They're going to have to find a way of having the countries agree to change that formality in the TPP to 12 years…If Australia wants to be part of it, they have to meet our terms,”
Call to remove IP clauses from trade pact
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam, humanitarian aid organisation Médecins Sans Frontières calls for the removal of intellectual property provisions from the agreement
Clause for evergreening of patents dropped from RCEP: Nirmala
Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed today.
TPP heightens urgency for national drug coverage in Canada
Adopting a national pharmacare program would offset the higher drug prices expected with the ratification of the Trans-Pacific Partnership, write Tanishq Suryavanshi and Jake Hirsch-Allen.
Civil society letter to countries negotiating Regional Comprehensive Economic Partnership (RCEP)
We call on countries negotiating the RCEP agreement and to protect the flexibilities available under the WTO TRIPS agreement for Least Developed Countries (LDCs).
At landmark BRICS meet, India raises public health, pharma sector concerns
A high-level panel hosted by India discusses the issues of trade deals that inhibit access to medicines and also limit policy space for governments to legislate in public interest.
Standing up to patent bullying
The Ministry of Commerce must be cautious of Free Trade Agreements being negotiated with the European Union as well as the Regional Comprehensive Economic Partnership that further strengthen or extend intellectual property (IP) monopolies.
Is India holding the line against another TPP?
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.
Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license
The letter says that this dispute over the compulsory license could prejudice resources for a new initiative called "Paz Colombia", as well as the US FTA with Colombia, and access to the TPP.
New threat against affordable medicines in trade negotiations with India and ASEAN
Access to affordable medicines could be severely restricted for millions of people around the world under the current proposals in the Regional Comprehensive Economic Partnership (RCEP) trade agreement?